ZyVersa Therapeutics(US:ZVSA) Globenewswire·2025-04-24 11:57Core Insights - ZyVersa Therapeutics is focused on developing first-in-class drugs for renal and inflammatory diseases, specifically targeting chronic inflammatory conditions with its Inflammasome ASC Inhibitor IC 100 [1][2] Industry Overview - The global market for anti-inflammatory biologics was valued at $105 billion in 2024 and is projected to reach $186 billion by 2034, driven by the increasing incidence of chronic inflammatory diseases due to aging populations, lifestyle changes, and environmental factors [2] - Over the past five years, there have been over $7 billion in strategic collaborations and M&A activities in the inflammasome inhibitor development space, indicating strong interest and investment in this area [3] Development Trends - The development of inflammasome inhibitors is at a critical juncture, with many developers completing preclinical programs and early-phase clinical trials showing promising safety and efficacy signals [5] - Initial indications for inflammasome inhibitors are being identified, with many companies moving into phase 1b and phase 2 clinical trials, which are expected to yield data by the end of the year [5] Product Development - IC 100 is designed to uniquely inhibit ASC and ASC specks, aiming to control inflammation more effectively than targeting a single inflammasome [6][8] - A proof-of-concept study for IC 100 in a diet-induced obesity mouse model is planned for H1-2025, with preliminary results expected in H2-2025 [11] - An Investigational New Drug Application (IND) for IC 100 is anticipated to be submitted in H2-2025, followed by a Phase 1 clinical trial in overweight subjects [11]